Company / R&D Expense
GT Biopharma, Inc. R&D Expense History
FY2011-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$1.7M
FY2020
5-year range
$0 / $1.7M
FY2016-FY2020
Trend
+71.0%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $1M to $2M over the past 4 years.
Based on SEC 10-K filings.
$2M in FY2020 with a 3-year CAGR of +19.6%.
Improved from $1M to $2M over the past 4 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +19.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +19.6%, indicating consistent growth.
- In FY2020, r&d expense increased 71.0% year-over-year.
- Lowest r&d expense in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | $1.7M | +71.0% |
| FY2017 | $975.0K | -2.5% |
| FY2016 | $1.0M | - |
| FY2015 | $0 | - |
| FY2014 | $0 | - |
| FY2013 | $0 | -100.0% |
| FY2012 | $17.0K | -90.5% |
| FY2011 | $179.0K | - |
As of FY2020 · SEC 10-K · Updated Jun 24, 2026